SYS-CON MEDIA Authors: Adine Deford, Cynthia Dunlop, Harry Trott, Xenia von Wedel, Peter Silva

News Feed Item

Spinal Stenosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Stenosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Spinal Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Spinal Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Stenosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Stenosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Spinal Stenosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Sucampo Pharmaceuticals, Inc. 31
Clinical Trial Overview of Sucampo Pharmaceuticals, Inc. 31
Mesoblast Limited 32
Clinical Trial Overview of Mesoblast Limited 32
Zimmer Holdings, Inc. 33
Clinical Trial Overview of Zimmer Holdings, Inc. 33
United Therapeutics Corporation 34
Clinical Trial Overview of United Therapeutics Corporation 34
Nissan Chemical Industries, Ltd. 35
Clinical Trial Overview of Nissan Chemical Industries, Ltd. 35
LTT Bio-Pharma Co., Ltd. 36
Clinical Trial Overview of LTT Bio-Pharma Co., Ltd. 36
KT&G Corporation 37
Clinical Trial Overview of KT&G Corporation 37
Kaken Pharmaceutical Co., Ltd. 38
Clinical Trial Overview of Kaken Pharmaceutical Co., Ltd. 38
Biomet, Inc. 39
Clinical Trial Overview of Biomet, Inc. 39
Clinical Trial Overview of Top Institutes / Government 40
Seoul National University Hospital 40
Clinical Trial Overview of Seoul National University Hospital 40
Keio University 41
Clinical Trial Overview of Keio University 41
Hamamatsu University School of Medicine 42
Clinical Trial Overview of Hamamatsu University School of Medicine 42
University of Pittsburgh 43
Clinical Trial Overview of University of Pittsburgh 43
Vanderbilt University 44
Clinical Trial Overview of Vanderbilt University 44
Leiden University Medical Center 45
Clinical Trial Overview of Leiden University Medical Center 45
Yonsei University 46
Clinical Trial Overview of Yonsei University 46
Dartmouth-Hitchcock Medical Center 47
Clinical Trial Overview of Dartmouth-Hitchcock Medical Center 47
Emory University 48
Clinical Trial Overview of Emory University 48
Federal University of Sao Paulo 49
Clinical Trial Overview of Federal University of Sao Paulo 49
Five Key Clinical Profiles 50
Appendix 68
Abbreviations 68
Definitions 68
Research Methodology 69
Secondary Research 69
About GlobalData 70
Contact Us 70
Disclaimer 70
Source 70

List of Tables

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Stenosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sucampo Pharmaceuticals, Inc., 2014* 31
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mesoblast Limited, 2014* 32
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Zimmer Holdings, Inc., 2014* 33
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by United Therapeutics Corporation, 2014* 34
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nissan Chemical Industries, Ltd., 2014* 35
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by LTT Bio-Pharma Co., Ltd., 2014* 36
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by KT&G Corporation, 2014* 37
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaken Pharmaceutical Co., Ltd., 2014* 38
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biomet, Inc., 2014* 39
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 40
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Keio University, 2014* 41
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamamatsu University School of Medicine, 2014* 42
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 43
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2014* 44
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 45
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014* 46
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Dartmouth-Hitchcock Medical Center, 2014* 47
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 48
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2014* 49

List of Figures

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 69


To order this report: Spinal Stenosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
"We help companies that are using a lot of Software as a Service. We help companies manage and gain visibility into what people are using inside the company and decide to secure them or use standards to lock down or to embrace the adoption of SaaS inside the company," explained Scott Kriz, Co-founder and CEO of Bitium, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
15th Cloud Expo, which took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the conference content of @ThingsExpo, Big Data Expo, and DevOps Summit to include two developer events. IBM held a Bluemix Developer Playground on November 5 and ElasticBox held a Hackathon on November 6. Both events took place on the expo floor. The Bluemix Developer Playground, for developers of all levels, highlighted the ease of use of Bluemix, its services and functionalit...
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone far and beyond the capabilities of "traditional" system-level monitoring tools and approaches and requires much broader knowledge of business and applications as a whole. The goal of DevOps is to connect all aspects of app...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's large...
SAP is delivering break-through innovation combined with fantastic user experience powered by the market-leading in-memory technology, SAP HANA. In his General Session at 15th Cloud Expo, Thorsten Leiduck, VP ISVs & Digital Commerce, SAP, discussed how SAP and partners provide cloud and hybrid cloud solutions as well as real-time Big Data offerings that help companies of all sizes and industries run better. SAP launched an application challenge to award the most innovative SAP HANA and SAP HANA...
Want to enable self-service provisioning of application environments in minutes that mirror production? Can you automatically provide rich data with code-level detail back to the developers when issues occur in production? In his session at DevOps Summit, David Tesar, Microsoft Technical Evangelist on Microsoft Azure and DevOps, will discuss how to accomplish this and more utilizing technologies such as Microsoft Azure, Visual Studio online, and Application Insights in this demo-heavy session.
When an enterprise builds a hybrid IaaS cloud connecting its data center to one or more public clouds, security is often a major topic along with the other challenges involved. Security is closely intertwined with the networking choices made for the hybrid cloud. Traditional networking approaches for building a hybrid cloud try to kludge together the enterprise infrastructure with the public cloud. Consequently this approach requires risky, deep "surgery" including changes to firewalls, subnets...
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water,...
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation of details. It's the vision of a world in which continuous Internet connectivity and addressability is embedded into a growing range of human artifacts, into the natural world, and even into our smartphones, appliances, a...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happe...
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!